94 related articles for article (PubMed ID: 17951206)
1. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
Hameed O; Chhieng DC; Adams AL
Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
[TBL] [Abstract][Full Text] [Related]
2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Dolan M; Snover D
Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
[TBL] [Abstract][Full Text] [Related]
3. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
5. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis.
Hameed O; Adams AL; Baker AC; Balmer NE; Bell WC; Burford HN; Chhieng DC; Jhala NC; Klein MJ; Winokur T
Am J Clin Pathol; 2008 Sep; 130(3):425-7. PubMed ID: 18701416
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
Sauter G; Lee J; Bartlett JM; Slamon DJ; Press MF
J Clin Oncol; 2009 Mar; 27(8):1323-33. PubMed ID: 19204209
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
8. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer.
Liu YH; Xu FP; Rao JY; Zhuang HG; Luo XL; Li L; Luo DL; Zhang F; Xu J
Am J Clin Pathol; 2009 Jul; 132(1):74-9. PubMed ID: 19864236
[TBL] [Abstract][Full Text] [Related]
9. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy.
Bloom K; Harrington D
Am J Clin Pathol; 2004 May; 121(5):620-30. PubMed ID: 15151201
[TBL] [Abstract][Full Text] [Related]
10. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu analysis in breast cancer bone metastases.
Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
Graham AD; Faratian D; Rae F; Thomas JS
Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
[TBL] [Abstract][Full Text] [Related]
14. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.
Wang S; Saboorian MH; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Wians FH; Hynan L; Ashfaq R
Am J Clin Pathol; 2001 Oct; 116(4):495-503. PubMed ID: 11601134
[TBL] [Abstract][Full Text] [Related]
15. The clinical evaluation of HER-2 status: which test to use?
Bartlett J; Mallon E; Cooke T
J Pathol; 2003 Apr; 199(4):411-7. PubMed ID: 12635130
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Egervari K; Szollosi Z; Nemes Z; Kaczur V
Am J Clin Pathol; 2006 Jan; 125(1):155-6. PubMed ID: 16483004
[No Abstract] [Full Text] [Related]
17. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
[TBL] [Abstract][Full Text] [Related]
18. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of brain metastases in patients with HER-2/neu-positive breast carcinoma.
Altaha R; Crowell E; Hobbs G; Higa G; Abraham J
Cancer; 2005 Feb; 103(3):442-3. PubMed ID: 15578684
[No Abstract] [Full Text] [Related]
20. Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Moeder CB; Giltnane JM; Harigopal M; Molinaro A; Robinson A; Gelmon K; Huntsman D; Camp RL; Rimm DL; ;
J Clin Oncol; 2007 Dec; 25(34):5418-25. PubMed ID: 18048824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]